Institutional members access full text with Ovid®

Share this article on:

Use of 111In-Pentetreotide Scan in a Subject With Treatment Refractory Atypical Meningioma

Bural, Gonca G. MD*; Lieberman, Frank MD; Mountz, James M. MD, PhD*

doi: 10.1097/RLU.0000000000000326
Interesting Images

A 57-year-old man with a history of multiple recurrent atypical meningiomas (World Health Organization grade II) had several surgical resections including γ knife resection of the parafalcine meningioma, followed with a stereotactic radiosurgical ablation. Despite these treatments, an MRI scan performed 7 months later showed progression of the disease. The patient remained symptomatic with intermittent severe headaches associated with nausea, vomiting, and visual disturbance. He had a positive 111In-pentetreotide indicating the presence of somatostatin receptors. Therefore, he was placed on systemic Sandostatin (octreotide acetate) treatment, and at follow-up, he was clinically responsive to treatment.

From the *Division of Nuclear Medicine, Department of Radiology, and †Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA.

Received for publication October 24, 2012; revision accepted November 4, 2013.

Conflicts of interest and sources of funding: Supported in part by the National Institutes of Health grant U01 CA140230 through Dr Mountz. The authors have no conflict of interest to declare.

Reprints: Gonca G. Bural, MD, Division of Nuclear Medicine, Department of Radiology, University of Pittsburgh Medical Center, University of Pittsburgh, 200 Lothrop St, Pittsburgh, PA 15213. E-mail:

© 2014 by Lippincott Williams & Wilkins